ZN MEXICO L.P. REDUCES ITS EQUITY STAKE IN GENOMMA

*Genomma Lab Internacional S.A.B. de C.V.* (BMV: LAB) (“Genomma Lab” or “the Company”) makes of public investor knowledge that its shareholder ZN Mexico II L.P., the private equity fund administered by Nexxus Capital S.A. de C.V., has realized diverse alienations of representative stock of LAB’s equity, since the initial public offering realized on June 18th, 2008 until today, which have resulted in a decrease in this shareholder’s participation in 5.04% of LAB’s equity. As a result of these alienations, the number of stocks in the public’s hands to date is above 32.3% of the total stocks in circulation.

**Company Description**

*Genomma Lab Internacional, S.A.B. de C.V.* is one of the fastest growing pharmaceutical and personal care products companies in Mexico and has a growing international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has significantly grown its revenue and profitability through a combination of a successful new product development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Web page: [www.genommalab.com](http://www.genommalab.com)

---

**Contact:**

Oscar Villalobos-Torres
Tel: +52 (55) 5081 0000 ext 4250
inversion@genommalab.com

In New York: i-advize Corporate Communications, Inc.
Tel: (212) 406-3692
E-mail: genomma@i-advize.com